We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.
For more information visit our privacy policy.Common Contracts
2 similar License Agreement contracts by BridgeBio Pharma, Inc., Eidos Therapeutics, Inc.
LICENSE AGREEMENT between Alexion Pharma International Operations Unlimited Company and Eidos Therapeutics, Inc. DATED September 9, 2019License Agreement • November 8th, 2019 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (this “Agreement”) is made as of September 9, 2019 (the “Effective Date”), by and between Eidos Therapeutics, Inc., a Delaware corporation (“Eidos”), having a place of business at 101 Montgomery Street, Suite 2550, San Francisco, California 94104, USA, and Alexion Pharma International Operations Unlimited Company, an Irish unlimited company (“Alexion”), having a place of business at College Business & Technology Park, Blanchardstown, Dublin 15, Ireland. Eidos and Alexion are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Standard Contracts
LICENSE AGREEMENT between Alexion Pharma International Operations Unlimited Company and Eidos Therapeutics, Inc. DATED September 9, 2019License Agreement • October 31st, 2019 • Eidos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (this “Agreement”) is made as of September 9, 2019 (the “Effective Date”), by and between Eidos Therapeutics, Inc., a Delaware corporation (“Eidos”), having a place of business at 101 Montgomery Street, Suite 2550, San Francisco, California 94104, USA, and Alexion Pharma International Operations Unlimited Company, an Irish unlimited company (“Alexion”), having a place of business at College Business & Technology Park, Blanchardstown, Dublin 15, Ireland. Eidos and Alexion are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”